Seminars in Thoracic and Cardiovascular Surgery最新文献

Just Short of the Silver Medal: The Radial is a Close Third to the Right Internal Thoracic Artery in the Hierarchy of Arterial Coronary Bypass Grafts.

IF 2.6 3区医学

Seminars in Thoracic and Cardiovascular Surgery Pub Date : 2025-04-04 DOI: 10.1053/j.semtcvs.2025.01.009

Michael Salna, Michael Argenziano, Craig R Smith

引用次数: 0

Arrhythmic Mitral Valve Prolapse: Pathophysiology, Diagnostics, and Management Strategies.

IF 2.6 3区医学

Seminars in Thoracic and Cardiovascular Surgery Pub Date : 2025-04-04 DOI: 10.1053/j.semtcvs.2025.03.005

Jagdip Kang, Antonia van Kampen, Maja Theresa Dieterlen, Ricardo Spampinato, Thoralf Sundt, Serguei Melnitchouk, Robert A Levine, Michael A Borger

引用次数: 0

Aortic Aneurysmectomy: The ACC/AHA Guidelines. 主动脉瘤切除术：ACC/AHA 指南。

IF 2.6 3区医学

Seminars in Thoracic and Cardiovascular Surgery Pub Date : 2025-04-04 DOI: 10.1053/j.semtcvs.2025.03.007

Davut Cekmecelioglu, Ourania Preventza

引用次数: 0

Spinal cord ischemia prevention and management in thoracoabdominal branched endovascular aortic repair.

IF 2.6 3区医学

Seminars in Thoracic and Cardiovascular Surgery Pub Date : 2025-04-02 DOI: 10.1053/j.semtcvs.2025.03.003

Jesse Chait, Armin Tabiei, Gustavo S Oderich, Bernardo C Mendes

引用次数: 0

Aortic Valve Repair: Wisdom or Folly?

IF 2.6 3区医学

Seminars in Thoracic and Cardiovascular Surgery Pub Date : 2025-03-26 DOI: 10.1053/j.semtcvs.2025.03.004

David Blitzer, Emile Bacha

引用次数: 0

Atrial Dysfunction Induced Mitral Regurgitation: A Different Problem with a Different Solution. 心房功能障碍诱发二尖瓣反流：不同的问题，不同的解决方案。

IF 2.6 3区医学

Seminars in Thoracic and Cardiovascular Surgery Pub Date : 2025-03-20 DOI: 10.1053/j.semtcvs.2025.03.001

Matthew Kazaleh, Catherine Wagner, Steven F Bolling

引用次数: 0

Partial Heart Transplant Update: Where Are We In 2025?

IF 2.6 3区医学

Seminars in Thoracic and Cardiovascular Surgery Pub Date : 2025-03-19 DOI: 10.1053/j.semtcvs.2025.03.002

Seth E M Wolf, Berk Aykut, Cathlyn K Medina, John A Kucera, Hiba Z Ghandour, Joseph W Turek, Douglas M Overbey

{"title":"Partial Heart Transplant Update: Where Are We In 2025?","authors":"Seth E M Wolf, Berk Aykut, Cathlyn K Medina, John A Kucera, Hiba Z Ghandour, Joseph W Turek, Douglas M Overbey","doi":"10.1053/j.semtcvs.2025.03.002","DOIUrl":"10.1053/j.semtcvs.2025.03.002","url":null,"abstract":"Partial heart transplantation (PHT) creates a new and innovative approach to allow for patient and disease tailored intervention with the ability to treat a larger patient base. It offers the growth capacity of a heart transplantation without the need for high dose immunosuppression. The importance of a valve replacement with the potential of growth is imperative in the pediatric population as these patients will otherwise outgrow their new valves requiring repeat and high-risk interventions. Adaptive valve growth has been observed prior to PHT, in the case of orthotopic heart transplantation and Ross pulmonary autografts. The first human PHT was performed in April of 2022 at Duke. The recipient was a 17-day old infant with truncus arteriosus and severe truncal valve regurgitation. The operation was a success and the transplanted PHT conduit showed appropriate adaptive valve growth. Due to the low immunogenicity and recipient endothelialization of the transplanted PHT graft, the immunosuppressive requirements for PHT patients are low. One of the benefits of PHT is that it utilizes hearts which would otherwise not be suitable for orthotopic heart transplantation. Furthermore, the prospect of domino and split root PHT increases the potential of ethical and efficient organ stewardship. Currently PHT is regulated by the Food and Drug Administration, a ruling which was released in early 2024 as human cells, tissues, or cellular or tissue-based products (HCT/Ps). This means it does not compete with hearts suitable for orthotopic heart transplantation which are regulated as organs under the Organ Procurement and Transplantation Network (OPTN).","PeriodicalId":48592,"journal":{"name":"Seminars in Thoracic and Cardiovascular Surgery","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143674764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Commando Operation. 突击队行动

IF 2.6 3区医学

Seminars in Thoracic and Cardiovascular Surgery Pub Date : 2025-03-18 DOI: 10.1053/j.semtcvs.2025.02.009

Tirone E David, Malak Elbatarny

引用次数: 0

Congenital Heart Surgery Workforce Issues.

IF 2.6 3区医学

Seminars in Thoracic and Cardiovascular Surgery Pub Date : 2025-03-13 DOI: 10.1053/j.semtcvs.2025.02.006

Brian Kogon, Jay Patel

引用次数: 0

Current Status of Treatment for the Acute Type A Aortic Dissection in Japan.

IF 2.6 3区医学

Seminars in Thoracic and Cardiovascular Surgery Pub Date : 2025-03-12 DOI: 10.1053/j.semtcvs.2025.02.008

Yutaka Okita

{"title":"Current Status of Treatment for the Acute Type A Aortic Dissection in Japan.","authors":"Yutaka Okita","doi":"10.1053/j.semtcvs.2025.02.008","DOIUrl":"10.1053/j.semtcvs.2025.02.008","url":null,"abstract":"Presenting the current status of patient outcomes with acute type A aortic dissection in Japan. The Japanese Association for Thoracic Surgery (JATS), Japanese Registry of All cardiac and Vascular Disease (JROAD), Japan Registry of Acute Aortic Dissection (JRAD), Japan Cardiovascular Surgery Database (JCVSD), National Clinical Database (NCD), The Tokyo acute aortic super network, and J-Open caRdiac aortic arCH DisEase replacement Surgical TheRApy (J-ORCHESTRA) database were used. The incidence of AAD ranged from 10 to 20 per 100,000 population. Thirty percent of patients were older than 70 years. Malperfusion syndrome or ruptured aorta was found in 10-20%. Over 90% of patients had surgery within 24-hour after diagnosis. The mortality tended to be higher in the super-acute phases from onset to surgical treatment. Acute organ malperfusion requires an accurate and prompt diagnosis to proceed with an appropriate intervention before repairing the central aorta. Antegrade cerebral perfusion was used in 70-80% and deep hypothermic circulatory arrest with/without retrograde cerebral perfusion in 20-30%. High-moderate or mild hypothermia was applied in more than 50% of patients. Replacement of the ascending aorta was performed in 70% and total arch replacement in 30%. Treatment with frozen elephant trunk as well as thoracic endovascular aortic repair (TEVAR) has increased. The aortic valve was replaced in 8-10%. Thirty-day mortality was 9.0-10%. The number of operations has increased over time. Stroke occurred in 10-12%. Although the early outcomes are acceptable, there is still room to be improved in patients with preoperative comorbidities.","PeriodicalId":48592,"journal":{"name":"Seminars in Thoracic and Cardiovascular Surgery","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143630949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0